Readystate Asset Management LP Sells 95,547 Shares of Vaxcyte, Inc. $PCVX

Readystate Asset Management LP decreased its position in Vaxcyte, Inc. (NASDAQ:PCVX) by 72.6% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 36,090 shares of the company’s stock after selling 95,547 shares during the period. Readystate Asset Management LP’s holdings in Vaxcyte were worth $2,097,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in PCVX. Smartleaf Asset Management LLC boosted its position in Vaxcyte by 156.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock valued at $27,000 after buying an additional 364 shares during the period. Caitong International Asset Management Co. Ltd increased its position in shares of Vaxcyte by 1,463.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock valued at $30,000 after acquiring an additional 600 shares during the period. EverSource Wealth Advisors LLC increased its position in shares of Vaxcyte by 33.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock valued at $34,000 after acquiring an additional 184 shares during the period. Capital Advisors Ltd. LLC bought a new position in shares of Vaxcyte during the first quarter valued at about $58,000. Finally, Allworth Financial LP raised its stake in shares of Vaxcyte by 148.9% during the third quarter. Allworth Financial LP now owns 1,222 shares of the company’s stock valued at $44,000 after acquiring an additional 731 shares during the last quarter. 96.78% of the stock is currently owned by institutional investors.

Vaxcyte Price Performance

Shares of NASDAQ PCVX opened at $54.60 on Wednesday. Vaxcyte, Inc. has a 1 year low of $29.08 and a 1 year high of $65.00. The stock has a market capitalization of $7.88 billion, a P/E ratio of -7.94 and a beta of 1.22. The company’s 50-day moving average is $52.83 and its 200 day moving average is $54.77.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($2.30) EPS for the quarter, missing the consensus estimate of ($1.74) by ($0.56). During the same period last year, the firm posted ($1.04) EPS. Research analysts anticipate that Vaxcyte, Inc. will post -7.91 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently issued reports on PCVX shares. Zacks Research cut Vaxcyte from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. Wall Street Zen lowered Vaxcyte from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 28th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a report on Monday, July 6th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Vaxcyte currently has a consensus rating of “Hold” and a consensus price target of $86.00.

Insider Transactions at Vaxcyte

In other news, CEO Grant Pickering sold 22,461 shares of the firm’s stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $52.50, for a total value of $1,179,202.50. Following the completion of the transaction, the chief executive officer owned 474,703 shares in the company, valued at $24,921,907.50. This trade represents a 4.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 2,250 shares of Vaxcyte stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $49.52, for a total value of $111,420.00. Following the sale, the chief operating officer owned 158,494 shares in the company, valued at $7,848,622.88. This represents a 1.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 93,646 shares of company stock valued at $5,103,592. Corporate insiders own 3.30% of the company’s stock.

Vaxcyte Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.